{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T14:19:40Z","timestamp":1747145980594,"version":"3.40.5"},"reference-count":35,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We present long\u2010term combined results of two clinical trials implementing R\u2010MACLO\u2010IVAM induction followed by thalidomide or rituximab maintenance in 44 patients with untreated mantle cell lymphoma (MCL). The first 22 patients (UM\u2010MCL1 <jats:italic>ClinicalTrials.gov<\/jats:italic> identifier NCT00450801) received maintenance with thalidomide (200\u2009mg daily until relapse\/intolerable toxicity) and a subsequent cohort of 22 patients (UM\u2010MCL2 <jats:italic>ClinicalTrials.gov<\/jats:italic> identifier NCT00878254) received rituximab (375\u2009mg\/m<jats:sup>2<\/jats:sup> IV weekly\u2009\u00d7\u20094, repeated every 6\u00a0months for 3\u2009years). Considering all 44 patients, 41 (93.2%) achieved complete response (CR), two (4.5%) partial response (PR), and one (2.3%) was not evaluated for response. With a median follow up of 7.2\u2009years (range\u2009&lt;\u20091\u00a0month to 16\u2009years), the 5\u2010year progression\u2010free survival (PFS) was 55.6% (95% CI: 38.9%\u201069.4%) and median PFS 7.9\u2009years (95% CI: 3.7\u201311\u2009years). The 5\u2010year OS was 83.3% (95% CI: 68.1%\u201091.7%) and median OS was not reached. Patients with blastic variant (n\u00a0=\u00a06) had a 5\u2010year PFS and OS of 20.8% and 60%, respectively. Myelosuppression was the most common adverse event during immunochemotherapy. Long\u2010term treatment\u2010related mortality was 6.8%. Note, R\u2010MACLO\u2010IVAM followed by maintenance therapy is an effective regimen to induce long\u2010term remission in MCL without need for consolidation with ASCT.<\/jats:p>","DOI":"10.1002\/ajh.26163","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T16:30:31Z","timestamp":1616085031000},"page":"680-689","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["<scp>R\u2010MACLO\u2010IVAM<\/scp> regimen followed by maintenance therapy induces durable remissions in untreated mantle cell lymphoma \u2010 Long term follow up results"],"prefix":"10.1002","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2690-3377","authenticated-orcid":false,"given":"Juan P.","family":"Alderuccio","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Hematology, Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine  Miami Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo E.","family":"Saul","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Internal Medicine, Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine  Miami Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2507-9347","authenticated-orcid":false,"given":"Sunil G.","family":"Iyer","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology, Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine  Miami Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isildinha M.","family":"Reis","sequence":"additional","affiliation":[{"name":"Department of Public Health Science, Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine  Miami Florida"},{"name":"Sylvester Biostatistics and Bioinformatics Shared Resource, Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine  Miami Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1720-9295","authenticated-orcid":false,"given":"Alvaro J.","family":"Alencar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology, Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine  Miami Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph D.","family":"Rosenblatt","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology, Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine  Miami Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9346-9013","authenticated-orcid":false,"given":"Izidore S.","family":"Lossos","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology, Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine  Miami Florida"},{"name":"Department of Molecular and Cellular Pharmacology, Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine  Miami Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,4,7]]},"reference":[{"doi-asserted-by":"publisher","key":"e_1_2_9_2_1","DOI":"10.1182\/blood-2018-03-791392"},{"volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","year":"2017","author":"Swerdlow SH","key":"e_1_2_9_3_1"},{"doi-asserted-by":"publisher","key":"e_1_2_9_4_1","DOI":"10.1002\/ajh.24797"},{"doi-asserted-by":"publisher","key":"e_1_2_9_5_1","DOI":"10.1093\/annonc\/mdn045"},{"doi-asserted-by":"publisher","key":"e_1_2_9_6_1","DOI":"10.1002\/hon.2596"},{"doi-asserted-by":"publisher","key":"e_1_2_9_7_1","DOI":"10.1016\/S0140-6736(16)00739-X"},{"doi-asserted-by":"publisher","key":"e_1_2_9_8_1","DOI":"10.1111\/j.1365-2141.2012.09174.x"},{"doi-asserted-by":"publisher","key":"e_1_2_9_9_1","DOI":"10.1182\/blood-2014-03-559930"},{"doi-asserted-by":"publisher","key":"e_1_2_9_10_1","DOI":"10.1182\/blood-2011-07-369629"},{"doi-asserted-by":"publisher","key":"e_1_2_9_11_1","DOI":"10.1111\/bjh.13796"},{"doi-asserted-by":"publisher","key":"e_1_2_9_12_1","DOI":"10.1200\/JCO.2005.01.1825"},{"doi-asserted-by":"publisher","key":"e_1_2_9_13_1","DOI":"10.1093\/annonc\/mdt070"},{"doi-asserted-by":"publisher","key":"e_1_2_9_14_1","DOI":"10.1111\/j.1365-2141.2011.08958.x"},{"doi-asserted-by":"publisher","key":"e_1_2_9_15_1","DOI":"10.1182\/blood-2008-03-147025"},{"doi-asserted-by":"publisher","key":"e_1_2_9_16_1","DOI":"10.1056\/NEJMoa1701769"},{"doi-asserted-by":"publisher","key":"e_1_2_9_17_1","DOI":"10.1056\/NEJMoa1200920"},{"issue":"15","key":"e_1_2_9_18_1","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1200\/JCO.2016.34.15_suppl.7503","article-title":"Two years rituximab maintenance vs. observation after first\u2010line treatment with bendamustine plus rituximab (B\u2010R) in patients with mantle cell lymphoma: first results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7\u20102008 MAINTAIN trial)","volume":"34","author":"Rummel MJ","year":"2016","journal-title":"J Clin Oncol"},{"doi-asserted-by":"publisher","key":"e_1_2_9_19_1","DOI":"10.1182\/blood-2019-129404"},{"doi-asserted-by":"publisher","key":"e_1_2_9_20_1","DOI":"10.3109\/10428190903518345"},{"doi-asserted-by":"publisher","key":"e_1_2_9_21_1","DOI":"10.1002\/ajh.23996"},{"key":"e_1_2_9_22_1","first-page":"1860","article-title":"Report of the committee on Hodgkin's disease staging classification","volume":"31","author":"Carbone PP","year":"1971","journal-title":"Cancer Res"},{"doi-asserted-by":"publisher","key":"e_1_2_9_23_1","DOI":"10.1200\/JCO.2013.54.8800"},{"unstructured":"NCI.Common Terminology Criteria for Adverse Events (CTCAE) version 4. National Cancer Institute;2010.","key":"e_1_2_9_24_1"},{"doi-asserted-by":"publisher","key":"e_1_2_9_25_1","DOI":"10.1200\/JCO.2015.63.8387"},{"doi-asserted-by":"publisher","key":"e_1_2_9_26_1","DOI":"10.1182\/blood-2007-06-095331"},{"unstructured":"Tamiflu and Aplastic anemia \u2010 a phase IV clinical study of FDA data.https:\/\/www.ehealthme.com\/ds\/tamiflu\/aplastic-anemia\/. Accessed February 26 2021.","key":"e_1_2_9_27_1"},{"doi-asserted-by":"publisher","key":"e_1_2_9_28_1","DOI":"10.3109\/10428194.2011.603443"},{"doi-asserted-by":"publisher","key":"e_1_2_9_29_1","DOI":"10.1111\/bjh.14241"},{"doi-asserted-by":"publisher","key":"e_1_2_9_30_1","DOI":"10.1200\/JCO.2013.49.2454"},{"doi-asserted-by":"publisher","key":"e_1_2_9_31_1","DOI":"10.1200\/JCO.18.00690"},{"doi-asserted-by":"publisher","key":"e_1_2_9_32_1","DOI":"10.1007\/s00277-013-1976-x"},{"doi-asserted-by":"publisher","key":"e_1_2_9_33_1","DOI":"10.1182\/asheducation-2016.1.437"},{"doi-asserted-by":"publisher","key":"e_1_2_9_34_1","DOI":"10.1182\/blood-2013-12-541953"},{"doi-asserted-by":"publisher","key":"e_1_2_9_35_1","DOI":"10.1182\/blood-2009-06-230250"},{"doi-asserted-by":"publisher","key":"e_1_2_9_36_1","DOI":"10.1182\/blood.V116.21.965.965"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.26163","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.26163","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.26163","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T05:29:24Z","timestamp":1693114164000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.26163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,7]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1002\/ajh.26163"],"URL":"https:\/\/doi.org\/10.1002\/ajh.26163","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"type":"print","value":"0361-8609"},{"type":"electronic","value":"1096-8652"}],"subject":[],"published":{"date-parts":[[2021,4,7]]},"assertion":[{"value":"2020-12-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}